X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

NRXP

Closed

Nrx Pharmaceuticals Inc

3.13
-0.13 (-3.99%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 3.26
Day's Range: 3.1 - 3.25
Send
When Written:
 
0.579
NRX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that focuses on developing novel therapies for central nervous system (CNS) disorders. The company's lead product candidate, NRX-101, is a nasal spray formulation of ketamine, a well-known anesthetic drug that is being developed for the treatment of major depressive disorder (MDD) and suicidal ideation.

NRX-101 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of MDD and is currently in Phase 2 clinical trials. The company is also developing NRX-102, a long-acting oral formulation of ketamine, for the treatment of MDD and other CNS disorders.

In addition to its ketamine-based product candidates, NRX Pharmaceuticals is also developing NRX-103, a combination of two FDA-approved drugs, d-cycloserine and lurasidone, for the treatment of cognitive impairment associated with schizophrenia.

NRX Pharmaceuticals was founded in 2015 and is headquartered in New York, NY.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X